HORIZON Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HORIZON, and what generic alternatives to HORIZON drugs are available?
HORIZON has nine approved drugs.
There are fifty-seven US patents protecting HORIZON drugs.
There are two hundred and thirty-one patent family members on HORIZON drugs in forty-four countries and one hundred and one supplementary protection certificates in eighteen countries.
Summary for HORIZON
| International Patents: | 231 |
| US Patents: | 57 |
| Tradenames: | 7 |
| Ingredients: | 7 |
| NDAs: | 9 |
| Patent Litigation for HORIZON: | See patent lawsuits for HORIZON |
| PTAB Cases with HORIZON as patent owner: | See PTAB cases with HORIZON as patent owner |
Drugs and US Patents for HORIZON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Horizon | PROCYSBI | cysteamine bitartrate | GRANULE, DELAYED RELEASE;ORAL | 213491-001 | Feb 14, 2020 | RX | Yes | No | 9,192,590*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Horizon | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-001 | Apr 30, 2013 | RX | Yes | No | 9,233,077*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Horizon Therap Us | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | RX | Yes | Yes | 9,254,278 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Horizon | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-002 | Apr 30, 2013 | RX | Yes | Yes | 9,925,157*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Horizon Therap Us | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | RX | Yes | Yes | 9,962,359 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Horizon Therap Us | BUPHENYL | sodium phenylbutyrate | TABLET;ORAL | 020572-001 | May 13, 1996 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for HORIZON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-002 | Jul 26, 2012 | 6,488,960 | ⤷ Sign Up |
| Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | 9,707,181 | ⤷ Sign Up |
| Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | 5,714,504*PED | ⤷ Sign Up |
| Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | 6,369,085*PED | ⤷ Sign Up |
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-001 | Jul 26, 2012 | 6,488,960 | ⤷ Sign Up |
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-002 | Jul 26, 2012 | 8,394,407 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HORIZON drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Solution | 2.0% | ➤ Subscribe | 2014-06-03 |
| ➤ Subscribe | Delayed-release Tablet | 375 mg/20 mg and 500 mg/20 mg | ➤ Subscribe | 2010-11-05 |
| ➤ Subscribe | Oral Liquid | 1.1 g/mL | ➤ Subscribe | 2013-11-19 |
| ➤ Subscribe | Topical Solution | 1.5% | ➤ Subscribe | 2012-07-11 |
| ➤ Subscribe | Delayed-release Tablets | 1 mg, 2 mg, and 5 mg | ➤ Subscribe | 2012-11-26 |
| ➤ Subscribe | Tablets | 800 mg/26.6 mg | ➤ Subscribe | 2011-12-06 |
International Patents for HORIZON Drugs
Supplementary Protection Certificates for HORIZON Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2203431 | CR 2015 00014 | Denmark | ⤷ Sign Up | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119 |
| 1919458 | C300649 | Netherlands | ⤷ Sign Up | PRODUCT NAME: CYSTEAMINE; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130906 |
| 2203431 | CA 2015 00014 | Denmark | ⤷ Sign Up | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115 |
| 2380576 | 20C1048 | France | ⤷ Sign Up | PRODUCT NAME: SEL DE SODIUM DE L'ACIDE DESOXYCHOLIQUE; NAT. REGISTRATION NO/DATE: NL46299 20180810; FIRST REGISTRATION: IS - IS/1/16/071/01 20160729 |
| 0473687 | SPC/GB98/030 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204 |
| 2563920 | CR 2019 00001 | Denmark | ⤷ Sign Up | PRODUCT NAME: INOTERSEN AND SALT THEREOF, INCLUDING SODIUM SALTS; REG. NO/DATE: EU/1/18/1296 20180710 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
